经皮冠状动脉介入治疗6~12个月后患者抗栓治疗的研究进展  

Research progress of antithrombotic therapy in patients after 6-12 months of percutaneous coronary intervention

作　　者：赵志刚[1] 李彩榕 王胜楠 李雅超 雷梦杰 杨彦立[1] 安蕾 周海立[1] 王敬尧 孙雪 薛增明[1] Zhao Zhigang;Li Cairong;Wang Shengnan;Li Yachao;Lei Mengjie;Yang Yanli;An Lei;Zhou Haili;Wang Jingyao;Sun Xue;Xue Zengming(Department of Cardiology,Langfang People’s Hospital,Langfang Core Laboratory of Precision Treatment of Coronary Artery Disease,Langfang 065000,China)

机构地区：[1]廊坊市人民医院心内科、廊坊市冠心病精准治疗重点实验室,065000

出　　处：《中国心血管杂志》2023年第3期282-286,共5页Chinese Journal of Cardiovascular Medicine

基　　金：河北省重点研发计划自筹项目(182777166);廊坊市科学技术研究与发展计划自筹经费项目(2022013038)。

摘　　要：双联抗血小板治疗(DAPT)一直是冠状动脉粥样硬化性心脏病(CAD)患者经皮冠状动脉介入治疗(PCI)术后的标准药物治疗方案。当前指南建议,在无危及生命的出血风险情况下,急性冠状动脉综合征患者PCI术后DAPT时程至少12个月,慢性冠状动脉综合征患者DAPT时程至少6个月。但目前DAPT的最佳治疗时程及6~12个月后进一步抗栓方案的临床研究结果尚不一致。本文主要对CAD患者PCI术后DAPT时程的影响因素及6~12个月后的进一步抗栓方案进行综述,以期为临床实践提供参考。The dual antiplatelet therapy(DAPT)has been a standard drug regimen for the coronary atherosclerotic disease(CAD)patients after undergoing percutaneous coronary intervention(PCI).Current guidelines recommend that DAPT duration should be continued at least 12 months after PCI in acute coronary syndrome patients without the risk of life-threatening hemorrhage,while DAPT duration should be continued at least 6 months after PCI in the patients with chronic coronary syndromes.The factors affecting DAPT duration after PCI in CAD patients and the antithrombotic program longer than 6-12 months will be reviewed in this article to provide reference for clinical practice.

关 键 词：抗栓治疗 冠状动脉粥样硬化性心脏病 经皮冠状动脉介入治疗 高出血风险 高缺血风险 

分 类 号：R541.4[医药卫生—心血管疾病]